HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Money

Moderna sees revenue bump from international COVID vaccine sales

The company is making up for a decline in U.S. vaccine sales with better results elsewhere, continuing a turnaround that’s vaulted its stock price in 2026.

By BioPharma Dive · May 1, 2026 · via BioPharma Dive
Moderna sees revenue bump from international COVID vaccine sales

Image: BioPharma Dive

This is an aggregated industry headline. Read the full story at BioPharma Dive →

Tags
moneyformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Money
All Money →
Seaport’s $255M Upsized IPO Defies the Big Pharma M&A Pull
MoneyBriefing
Seaport’s $255M Upsized IPO Defies the Big Pharma M&A Pull
Seaport Therapeutics opted for a $255M Nasdaq IPO over an acquisition, underscoring renewed investor appetite …
May 3, 2026
Lilly touts 'encouraging' early days for Foundayo obesity launch, even as GLP-1 pill appears to lag Novo's
MoneyFiercePharma ↗
Lilly touts 'encouraging' early days for Foundayo obesity launch, even as GLP-1 pill appears to lag Novo's
As Eli Lilly gets off to the races with the launch of its flagship oral GLP-1 Foundayo, the Indianapolis drugm…
May 1, 2026
MoneyDrug Channels ↗
Where Gross-to-net Pressure Actually Lives After Launch
Today’s guest post comes from Cindy Baksh, Chief Product Officer at ConnectiveRx. Cindy explains that many gro…
May 1, 2026